Arrowstreet Capital, Limited Partnership Esperion Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.34 - $5.56 $64,542 - $107,441	-19,324 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $92,948 - $230,342	19,324 New	19,324 $97,000
Q1 2021 May 14, 2021	SELL	$25.12 - $36.89 $3.43 Million - $5.03 Million	-136,477 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$24.2 - $35.76 $276,243 - $408,200	11,415 Added 9.13%	136,477 $3.55 Million
Q3 2020 Nov 12, 2020	BUY	$31.18 - $52.71 $4,084 - $6,905	131 Added 0.1%	125,062 $4.65 Million
Q2 2020 Aug 12, 2020	BUY	$30.04 - $51.31 $2.61 Million - $4.45 Million	86,792 Added 227.57%	124,931 $6.41 Million
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $1.05 Million - $2.82 Million	38,139 New	38,139 $1.2 Million

213

128M

1.78M

1.27M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $116M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.